Morgan Stanley analyst Sean Laaman raised the firm’s price target on BeOne Medicines (ONC) to $383 from $350 and keeps an Overweight rating on the shares. The firm raised its peak sales estimate for sonrotoclax to about $2.4B as it views its prior peak sales estimate of about $1.8B as “too conservative” compared to the venetoclax consensus peak sales forecast, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines to present data from Phase 3 trials RATIONALE-307 and 312
- BeOne Medicines’ sonrotoclax granted Breakthrough Therapy Designation by FDA
- BeOne Medicines initiated with an Overweight at Barclays
- Optimistic Buy Rating for BeOne Medicines Driven by Promising Sonrotoclax Trial Results and Market Potential
- BeOne Medicines reports ‘positive’ results from Phase 1/2 study of sonrotoclax